JMDC (4483) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The Company posted higher revenue and earnings for the quarter, with expansion of its core Health Big Data Business driving performance. Revenue was ¥126.0B (¥107.2B in the previous year, YoY +17.5%), Operating Income was ¥18.2B (¥15.5B in the previous year, YoY +17.5%), Profit Before Tax was ¥16.9B (¥14.4B in the previous year, YoY +17.1%), and consolidated Net Income was ¥11.3B (¥9.6B in the previous year, YoY +18.3%). The gross margin improved by +2.2pt to 53.5% from 51.3% in the previous year, while the SG&A expense ratio also increased to 39.4% from 37.0%. As a result, the Operating Income margin remained flat at 14.5%, at approximately the same level as the previous year.

Factors Affecting Performance

【Revenue】The Health Big Data Business drove overall growth, generating revenue of ¥109.5B (86.9% of total revenue, YoY +19.1%), while Telemedicine generated revenue of ¥16.5B (13.1% of total revenue, YoY +8.2%), representing moderate growth. Overall revenue growth of YoY +17.5% was primarily attributable to the expansion of the Health Big Data Business.

【Profit and Loss】The gross margin improved to 53.5% from 51.3% in the previous year, but the SG&A expense ratio increased to 39.4% from 37.0%, leaving the Operating Income margin essentially flat at 14.5%, broadly in line with the previous year (14.47%→14.46%). Financial income was ¥0.2B compared with financial expenses of ¥1.5B, resulting in a slight year-on-year increase in net financial expenses; however, Profit Before Tax expanded to ¥16.9B (YoY +17.1%). The effective tax rate declined slightly to 32.9% from 33.6% in the previous year, lifting the growth rate of Net Income to ¥11.3B (YoY +18.3%). No extraordinary gains or losses were identified, and recurring operating results were the main source of earnings growth. In conclusion, the Company achieved higher revenue and earnings.

Segment Analysis

Segment profit is calculated on an EBITDA basis. Health Big Data generated EBITDA of ¥22.5B (YoY +17.2%), with a margin of 20.5%, a slight decline of -0.3pt from 20.9% in the previous year. Telemedicine generated EBITDA of ¥6.5B (YoY +21.8%), with its margin improving to 39.6% from 35.2% in the previous year (+4.4pt). In terms of scale, Health Big Data accounts for the majority of consolidated revenue and profit, while Telemedicine, although smaller in scale, supports consolidated profitability through improved margins as a high-margin business.

Key Financial Indicators

【Profitability】The Operating Income margin was 14.5%, flat from 14.5% in the same period of the previous year, while the Net Income margin improved modestly to 9.0% from 8.9%. The gross margin improved by +2.2pt to 53.5% from 51.3% in the previous year, effectively absorbing the increase in the SG&A expense ratio to 39.4% from 37.0%.【Cash Quality】Operating Cash Flow (OCF) of ¥62.2B was approximately 5.5 times Net Income of ¥11.3B, indicating that cash-generating capacity substantially exceeded the level of reported profit.【Investment Efficiency】ROE was 1.4% (quarterly result). Revenue is relatively small compared with total assets of ¥1,540.6B, and low asset turnover is a constraint on capital efficiency.【Financial Soundness】The Equity Ratio was 53.9%, up +1.1pt from 52.8% in the previous year, and cash and cash equivalents stood at ¥307.8B. Meanwhile, goodwill amounted to ¥625.8B, representing 40.6% of total assets and constituting a notable feature of the asset structure.

Cash Flow Analysis

Operating Cash Flow was ¥62.2B, an increase of +15.8% year on year, representing the subtotal of ¥77.8B after deducting corporate income tax payments of ¥14.4B and interest payments of ¥1.3B. From a working capital perspective, the collection of trade receivables contributed ¥81.1B, while a decrease in trade payables (-¥15.5B) and an increase in contract assets (-¥8.4B) partially offset this contribution; contract liabilities increased by ¥2.8B. Investing Cash Flow was -¥9.7B, primarily comprising acquisitions of property, plant and equipment of -¥1.9B and acquisitions of intangible assets of -¥4.4B, indicating a restrained level of investment. Financing Cash Flow was -¥34.2B, mainly due to repayment of long-term borrowings of -¥20.4B (including ¥9.8B of new borrowings), dividend payments of -¥11.8B, and transactions with non-controlling interests of -¥8.3B. Free Cash Flow was ¥52.5B, sufficiently covering the combined ¥13.7B in dividend payments and capital expenditures during the quarter.

Quality of Earnings

Profit for the quarter was generated primarily by the core business, with non-operating items being minor on a net basis (financial expenses of ¥1.5B versus financial income of ¥0.2B), and no temporary factors equivalent to extraordinary gains or losses were identified. The effective tax rate was 32.9% (33.6% in the previous year), within a normal range. Comprehensive income was ¥10.3B (¥10.2B attributable to owners of the parent), slightly below Net Income of ¥11.3B, as other comprehensive income was negative ¥1.1B. This was primarily attributable to a valuation loss of ¥1.0B on financial assets measured at fair value through other comprehensive income, representing a market-related factor separate from operating results. Operating Cash Flow substantially exceeded Net Income, indicating strong cash generation supporting earnings from an accrual perspective.

Earnings Forecast and Guidance

Progress against the full-year forecast was 20.8% for Revenue (¥126.0B/¥605.0B), 15.9% for Operating Income (¥18.2B/¥115.0B), and 15.7% for Net Income (¥11.3B/¥72.0B), all below the 25% implied by a simple quarterly allocation. Although an earnings forecast revision was indicated for the quarter, no revision was made to the dividend forecast. Contract liabilities increased to ¥17.7B from ¥14.8B at the end of the previous fiscal year, suggesting that a certain amount of potential future revenue recognition has accumulated.

Shareholder Returns

Dividend payments during the quarter totaled ¥11.8B (¥10.4B in the same period of the previous year). These payments relate to the year-end dividend for the previous fiscal year and do not directly correspond to Net Income for the quarter; therefore, the Payout Ratio is not calculated on a single-quarter basis. Free Cash Flow of ¥52.5B substantially exceeded the quarter’s dividend payment of ¥11.8B, indicating that sufficient cash resources were available to fund the dividend. No share repurchases were identified during the quarter.

Risk Factors

1. Goodwill concentration risk: Goodwill amounted to ¥625.8B, representing 40.6% of total assets and approximately 75.2% of net assets. This asset has accumulated through M&A and is large enough to be subject to impairment assessment if profitability declines in the future.

2. Business concentration risk: The Company relies on the Health Big Data Business for 86.9% of revenue, making its business structure susceptible to fluctuations in demand and the effects of the contract structure of a single business segment.

3. Working capital volatility: Trade receivables and notes receivable amounted to ¥159.1B (a significant decrease from ¥240.2B in the same period of the previous year), reflecting progress in collections. Meanwhile, contract assets increased to ¥8.9B from ¥0.5B at the end of the previous fiscal year, creating a structure in which cash flow is susceptible to fluctuations depending on the timing of revenue recognition and billing terms.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (it_telecom)

Profitability and Return

Both the Operating Income margin and Net Income margin exceed the industry median, placing the Company in the high-profitability group within the industry.

Growth and Capital Efficiency

The Revenue growth rate also exceeds the industry median and is close to the upper bound of the IQR, placing the Company in the high-growth group within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The gross margin improved by +2.2pt year on year, but the SG&A expense ratio also increased by +2.4pt, leaving the Operating Income margin at 14.5%, broadly unchanged from the previous year. The key focus going forward is whether revenue growth can translate directly into margin improvement.

2. Full-year progress was 20.8% for Revenue and 15.9% for Operating Income, below the 25% implied by a simple allocation. However, contract liabilities increased from the end of the previous fiscal year, suggesting potential for revenue recognition in the second half.

3. Goodwill represents 40.6% of total assets and 75.2% of net assets, making this a structural feature of the asset base that warrants continued monitoring.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type, explicit 5-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥1,205–¥1,275 at ±1% for the cost of equity, and ¥1,238–¥1,240 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Goodwill represents a high proportion of net assets, and the assumptions would change significantly if impairment were recognized.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).

(Calculation model: Residual Income Model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmark is reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

JMDC delivered a solid FY2027 Q1 operating performance, with revenue, operating income and profit attributable to owners all rising at broadly the same mid- to high-teens rate. Revenue increased 17.5% year on year to ¥12.61bn. Operating income rose 17.5% to ¥1.82bn. Profit attributable to owners increased 17.0% to ¥1.13bn, and basic EPS rose to ¥17.28 from ¥14.79. Gross profit grew 22.6% to ¥6.75bn, outpacing revenue growth. Consequently, the gross margin improved by 220bp year on year to 53.5%. Operating margin was effectively unchanged at 14.5%, as SG&A increased 24.9% to ¥4.96bn, faster than revenue. EBITDA increased 17.5% to ¥2.70bn and the EBITDA margin remained stable at 21.4%. Net margin was broadly stable at 9.0%, down marginally by approximately 3bp. Finance costs increased 36.0% to ¥151m, but the interest burden remained 0.926 and did not materially impair profit conversion. Operating cash flow was exceptionally strong at ¥6.22bn, or 5.50x net income, and free cash flow was ¥5.25bn. This cash generation was principally driven by an ¥8.11bn collection of receivables, while payables declined by ¥1.55bn and contract assets increased by ¥840m. Therefore, cash conversion is strong in the reported quarter but should not be extrapolated mechanically as recurring earnings cash conversion. The Health Big Data segment remained the core business, contributing 86.9% of revenue and 77.5% of segment EBITDA before corporate costs. Full-year guidance implies Q1 revenue progress of 20.8%, operating-income progress of 15.9%, and net-income progress of 15.7%, all moderately below a standard 25% first-quarter run rate but not by more than 10 percentage points. The principal strategic balance-sheet issue remains the acquisition-derived asset base: goodwill represents 40.6% of assets and 75.2% of equity. Overall, the quarter supports continued underlying growth in healthcare data and remote-medical services, while investors should focus on conversion of growth into operating-margin expansion, recurring cash generation excluding working-capital releases, deleveraging, and the carrying-value resilience of goodwill.

Profitability Analysis

The reported annualized DuPont ROE is 5.4%, decomposed into a 9.0% net profit margin, 0.327x annualized asset turnover, and 1.85x financial leverage. The principal constraint on ROE is low asset turnover, reflecting the sizable acquisition-related asset base, including ¥62.58bn of goodwill, rather than insufficient financial leverage. Financial leverage is moderate and slightly below levels that would indicate an aggressive equity-risk profile, with D/E at 0.85x and an equity ratio of 53.9%. Gross margin expanded to 53.5% from 51.3%, showing favorable revenue mix, pricing, or service-delivery economics. However, SG&A rose 24.9%, materially faster than 17.5% revenue growth, absorbing the gross-profit gain and leaving operating margin flat at 14.5%. This limits evidence of operating leverage in Q1. EBITDA margin also remained essentially flat at 21.4%, reinforcing that the margin gain occurred at gross-profit level rather than at the consolidated operating-profit level. The tax burden was 0.670, equivalent to a 32.9% effective tax rate, and was a modest drag on net-profit conversion. The interest burden of 0.926 indicates that finance costs remain manageable relative to EBIT; EBIT covered finance costs by about 12.1x in the quarter. Profit quality at the P&L level is sound because operating income, pretax income, and net income each grew in a narrow 17.0%-18.3% range, with no material reliance on other income. Sustainable ROE improvement requires higher utilization of the acquired asset base and containment of SG&A growth below, or at least in line with, revenue growth.

Growth Assessment

Growth was broad based across both reported segments. Health Big Data revenue increased 19.1% year on year to ¥10.96bn, while segment EBITDA increased 17.2% to ¥2.25bn; its EBITDA margin therefore eased modestly to 20.5% from 20.9%. Remote Medical revenue grew 8.2% to ¥1.65bn, while EBITDA increased 21.8% to ¥653m, lifting its EBITDA margin by 440bp to 39.6% from 35.2%. Health Big Data is the core business by operating contribution, generating ¥2.25bn of EBITDA versus ¥653m in Remote Medical. Remote Medical remains the higher-margin segment, although Health Big Data is the main determinant of consolidated growth due to its 86.9% share of revenue. Consolidated revenue growth of 17.5% is above the 9.3% full-year operating-income growth embedded in guidance, suggesting management assumes growth moderates and/or investment and cost pressures continue through the year. Q1 operating-income progress against full-year guidance is 15.9%, 9.1 percentage points below the standard 25% pace. Q1 net-income progress is 15.7%, 9.3 percentage points below the standard pace. The revenue progress rate of 20.8% is also below 25%, but by only 4.2 percentage points. The company has revised its forecast, making subsequent guidance execution and the assumptions behind that revision central monitoring items. The high gross margin and recurring, data-driven Health Big Data franchise support growth quality, but stable consolidated EBITDA margin shows that revenue scaling has not yet translated into stronger group-level operating leverage.

Financial Health

Liquidity is sound on the reported balance sheet. Current assets of ¥51.72bn exceeded current liabilities of ¥21.37bn, implying a current ratio of approximately 2.42x. Cash and cash equivalents of ¥30.78bn were 6.75x short-term borrowings of ¥4.56bn, so the reported liquidity-stress alert stating cash-to-short-term-debt of 0.00x is not supported by the stated cash and short-term-debt balances. Current assets also comfortably exceed short-term debt, limiting maturity-mismatch risk. Total interest-bearing debt was ¥40.44bn, comprising ¥4.56bn of short-term loans and ¥35.88bn of long-term loans; only 11.3% is short term. D/E of 0.85x is within the conservative benchmark and debt-to-capital is 32.7%, below the 40% investment-grade reference point. The reported Debt/EBITDA alert of 15.0x is a material caution if assessed against unannualized Q1 EBITDA of ¥2.70bn; under a simple annualized-Q1 EBITDA assumption, it would be approximately 3.7x. Accordingly, the root issue is not near-term liquidity but the extent to which debt capacity depends on sustained EBITDA generation from acquired businesses. Lease liabilities total ¥10.59bn, including ¥9.05bn non-current, and should be considered alongside borrowings in assessing fixed financial commitments. Goodwill is ¥62.58bn, equal to 75.2% of equity and 40.6% of total assets. This exceeds the 50% goodwill-to-equity warning threshold and makes the equity base sensitive to any impairment of acquired businesses. Receivables declined 33.8% year on year to ¥15.91bn, improving balance-sheet liquidity, although contract assets rose to ¥890m from ¥50m and should be monitored alongside receivable collections. Inventories increased 30.3% to ¥658m, but remain immaterial at 0.4% of assets.

Notable B/S Changes

Accounts receivable: -¥8.11bn (-33.8% YoY) to ¥15.91bn - substantial collection supported Q1 operating cash flow; lower receivables improve liquidity, but the remaining balance still corresponds to reported DSO of 115 days. Contract assets: +¥0.84bn from ¥0.05bn at the prior year-end comparison point to ¥0.89bn - increased unbilled contract balances partly offset receivable collections and should be monitored for conversion into billed receivables and cash. Inventories: +¥0.15bn (+30.3% YoY) to ¥0.66bn - percentage growth is notable, but the absolute balance remains immaterial at 0.4% of assets. Goodwill: ¥62.58bn, or 40.6% of total assets and 75.2% of equity - balance was broadly stable, but its unusually large concentration remains the principal impairment and acquisition-value-retention sensitivity.

Cash Flow Quality

Reported operating cash flow was ¥6.22bn, equivalent to 5.50x net income of ¥1.13bn, well above the 0.8x quality-warning threshold. Free cash flow was ¥5.25bn, providing substantial reported-period coverage for capital expenditure and cash dividends. The accruals ratio of -3.3% is consistent with strong reported cash realization. However, the main source of operating cash flow was an ¥8.11bn reduction in receivables, exceeding both quarterly operating income and net income. This working-capital release was partly offset by a ¥1.55bn reduction in payables, an ¥840m increase in contract assets, a ¥152m inventory increase, and ¥1.44bn of cash tax payments. Accordingly, OCF/EBITDA of 2.30x is unusually high and should be treated as collection-led rather than a normalized recurring conversion rate. The high receivable-days alert of 115 days is calculated on an annualized Q1 revenue basis and remains above the 60-day benchmark. Its root cause is the still-material ¥15.91bn receivable balance relative to quarterly revenue, although the year-on-year reduction in receivables is a favorable direction of travel. The impact is that quarterly OCF can be volatile as collection timing changes, even if underlying earnings remain stable. Investment outflows were limited to ¥968m, including ¥436m of intangible-asset purchases and ¥195m of tangible capex. CapEx/depreciation was 0.22x, below the 0.7x underinvestment threshold. This may support near-term FCF, but sustained sub-replacement investment could constrain data-platform, systems, and service-capacity development. Financing cash flow was negative ¥3.42bn, led by ¥2.04bn of long-term debt repayment, ¥1.18bn of dividend payments, ¥833m used for transactions with non-controlling interests, and ¥362m of lease payments, partly offset by ¥980m of new long-term borrowing.

Dividend Sustainability

Cash dividends paid were ¥1.18bn in FY2027 Q1. Reported FCF of ¥5.25bn covered the cash dividend by approximately 4.5x, indicating ample cash coverage in the period. Dividends paid slightly exceeded quarterly net income of ¥1.13bn, but payment timing means this comparison should not be interpreted as a formal dividend payout ratio. A DPS-based payout ratio cannot be calculated from the reported-period data. The balance sheet has sufficient liquidity, with ¥30.78bn of cash and a current ratio of approximately 2.42x. Dividend capacity is therefore not currently constrained by near-term liquidity. Nevertheless, normalized dividend capacity should be assessed against recurring FCF rather than Q1 cash flow, because the quarter benefited materially from receivable collections. Debt reduction, lease commitments, minority-interest transactions, and the need to preserve flexibility against goodwill impairment risk remain relevant capital-allocation calls on cash. No share repurchases were reported, so a total return ratio is not applicable.

Risk Assessment

Business risks include Healthcare-data and remote-medical growth may moderate relative to Q1, as the full-year forecast implies a slower growth profile than the 17.5% Q1 revenue increase., Health Big Data EBITDA margin declined modestly to 20.5% from 20.9%, while group SG&A grew 24.9%, faster than revenue; continued cost growth could prevent operating leverage., Industry-specific risk: handling and commercialization of sensitive medical and health data exposes the group to cybersecurity, privacy, data-governance, and healthcare-regulatory risks., Remote Medical has a materially higher 39.6% EBITDA margin but is smaller; competitive pressure, radiologist supply constraints, or reimbursement and healthcare-provider policy changes could affect profitability..

Financial risks include Goodwill of ¥62.58bn equals 75.2% of equity and 40.6% of assets. The root cause is the acquisition-led business model; the impact is potentially material equity and earnings sensitivity if acquired cash-generating units underperform and require impairment., The reported 15.0x Debt/EBITDA metric flags elevated leverage when compared with unannualized Q1 EBITDA. Although a simple annualized-Q1 basis would reduce the ratio to roughly 3.7x, debt service capacity remains dependent on sustained EBITDA performance and refinancing access., Goodwill/EBITDA is reported at 23.2x using Q1 EBITDA, above the 10x warning threshold. Even on a simple annualized-Q1 EBITDA basis of roughly 5.8x, the acquisition premium requires durable post-acquisition cash flows and successful integration., Receivable days of 115 are above the 60-day benchmark, creating timing sensitivity in operating cash flow despite the favorable year-on-year receivable reduction., CapEx/depreciation of 0.22x raises an underinvestment alert. The near-term cash benefit may be offset by longer-term risk if technology, data infrastructure, or service capacity investment does not keep pace with business needs..

Key concerns include Highest priority: goodwill impairment and M&A value-retention risk, given goodwill-to-equity of 75.2% and the importance of acquired earnings to debt capacity., High priority: sustaining revenue growth while restoring operating leverage, as SG&A growth exceeded revenue growth by 7.4 percentage points., Medium priority: cash-flow normalization after the ¥8.11bn receivable collection; reported OCF and FCF may not represent a steady quarterly run rate., Medium priority: management execution against revised full-year guidance, with Q1 operating-profit and net-profit progress both about 9 percentage points below a standard 25% pace., The reported liquidity-stress alert is not a current balance-sheet concern based on stated cash of ¥30.78bn and short-term loans of ¥4.56bn; its investment impact is limited unless the underlying metric definition differs from the reported balances..

Investment Implications

Key takeaways include Revenue growth of 17.5% and gross-margin expansion of 220bp demonstrate continued demand and favorable underlying service economics., Consolidated operating and EBITDA margins were flat because SG&A growth of 24.9% outpaced revenue growth., Health Big Data is the principal earnings engine, while Remote Medical provides a smaller but substantially higher-margin growth contribution., Reported cash generation is very strong, but the magnitude is driven by receivable collection and should be normalized in forward analysis., The capital structure is liquid and has a moderate D/E ratio, but the acquisition-led goodwill concentration is the central balance-sheet valuation and impairment sensitivity..

Metrics to watch include Health Big Data revenue growth and EBITDA margin, SG&A growth relative to revenue growth and consolidated operating-margin progression, Full-year guidance progress, particularly operating income versus the ¥11.50bn forecast, Receivables, contract assets, DSO, and operating cash flow excluding working-capital movements, Interest-bearing debt, lease liabilities, refinancing terms, and leverage on a full-year EBITDA basis, Goodwill impairment testing assumptions, acquired-business performance, and goodwill-to-equity.

Regarding relative positioning, JMDC combines high gross margins, healthcare-data exposure, and a high-margin Remote Medical business with an acquisition-heavy capital base. Its operating margin of 14.5% is at the upper end of the good benchmark range but just below the 15% excellent threshold, while annualized ROE of 5.4% and reported ROIC of 4.0% indicate that returns on the enlarged asset base remain the key area for improvement.